FDAnews Drug Daily Bulletin
Pharmaceuticals / Submissions and Approvals

FDA Approves First Non-Injected Glucagon Treatment for Severe Hypoglycemia

July 31, 2019

The FDA has approved Eli Lilly’s Baqsimi nasal powder 3 mg, making it the first needleless glucagon therapy OK’d by the agency for the emergency treatment of severe hypoglycemia.

The drug is the first and only nasally-administrated glucagon treatment indicated for diabetic patients aged four and above experiencing severe hypoglycemia, a dangerously low level of blood sugar.

The condition is very serious for type 1 and type 2 diabetes patients and can lead to seizures, comas and even death if not treated properly.

View today's stories